ArticleMolecular diagnosis & therapy2025
Human Papillomavirus Type and Viral Load in Relation to Circulating Cell-Free Tumour HPV DNA Level and Survival in Cervical Cancer.
Article in Molecular diagnosis & therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 1 synthesis or guideline pooled it.
- Prognostic Value of Pretreatment Circulating Tumor HPV DNA Load in HPV-Associated Cancers: A Systematic Review and Meta-Analysis.International journal of molecular sciences · 2026Pooled it
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
objectiveHuman papillomavirus (HPV) is the cause of most cervical cancers and is released as circulating cell-free tumour HPV DNA (ctHPV DNA) into circulation. Earlier studies have indicated that ctHPV DNA is a promising biomarker for analysing treatment response and for recurrence surveillance. However, factors influencing the release of ctHPV DNA, including HPV type and HPV viral load, have not been extensively studied and additional biomarkers for prognosis are needed. Therefore, here we analysed ctHPV DNA, HPV type and viral load in relation to each other and to progression-free survival in patients with locally advanced or advanced cervical cancer.
methodsPre-treatment biopsies and blood samples were collected from patients diagnosed with cervical cancer (Federation of Gynecology and Obstetrics [FIGO] stage IB-IV). One hundred and seventeen patients with HPV-positive tumours were included. Human papillomavirus type-specific, droplet digital polymerase chain reaction (ddPCR) assays were used to analyse previously genotyped biopsies for the viral load. Pre-treatment plasma from 92/117 patients were available and analysed for ctHPV DNA and total cell-free DNA levels. Results were related to patient and tumour characteristics and progression-free survival. Patients were grouped based on HPV species where alpha-9-species (including HPV16) and alpha-7-species (including HPV 18) constituted the majority of cases.
resultsCell-free tumour HPV DNA was found in 83/92 (90.2%) of pre-treatment plasma samples. Higher biopsy viral load was significantly related to a higher ctHPV DNA level. Higher stage and larger primary tumour size were also associated with higher ctHPV DNA level. Alpha-9 species, including HPV16, had a significantly higher viral load (16×), a higher ctHPV DNA level (17×), and a higher detection rate in plasma than alpha-7 species, including HPV18. Alpha-9 species also had significantly better progression-free survival than alpha-7 species. Additional factors leading to better progression-free survival included a lower stage, a lower total cell-free DNA level, a viral load in the 90th percentile and, in the high-risk cervical cancer group, a higher pre-treatment ctHPV DNA level.
conclusionsCell-free tumour HPV DNA, HPV type and viral load are promising biomarkers in cervical cancer. The lower sensitivity for ctHPV DNA detection for alpha-7 species, including HPV18, needs to be considered in future studies on ctHPV DNA, especially if used as a marker for relapse during surveillance when ctHPV DNA levels are very low.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.